Research Topics
Genomes and Genes
| FERGUS JOSEPH COUCHSummaryAffiliation: Mayo Clinic Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2Anna Marie Mulligan
Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK
Breast Cancer Res 13:R110. 2011..It is currently unknown how these alleles are associated with different breast cancer subtypes in BRCA1 and BRCA2 mutation carriers defined by estrogen (ER) or progesterone receptor (PR) status of the tumour...- Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriersFergus J Couch
Departments of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Cancer Epidemiol Biomarkers Prev 21:645-57. 2012..We explored associations with ovarian cancer and with breast cancer by tumor histopathology for these variants in mutation carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)... - Exploring the link between MORF4L1 and risk of breast cancerGriselda Martrat
Translational Research Laboratory, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research IDIBELL, Gran Via 199, L Hospitalet del Llobregat 08908, Spain
Breast Cancer Res 13:R40. 2011..To gain deeper insight into this pathway and its influence on cancer risk, we searched for novel components through protein physical interaction screens... - Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control studyRoger L Milne
Genetic and Molecular Epidemiology Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre CNIO, Madrid, 28029, Spain
Breast Cancer Res 12:R110. 2010.... - Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriersLogan C Walker
Division of Genetics and Population Health, Queensland Institute of Medical Research, Brisbane, Australia
Breast Cancer Res 12:R102. 2010..In this study, we evaluated 24 SNPs tagged to 14 candidate genes derived through a novel approach that analysed gene expression differences to prioritise candidate modifier genes for association studies... - Genetic variation in stromal proteins decorin and lumican with breast cancer: investigations in two case-control studiesLinda E Kelemen
Department of Population Health Research, Alberta Cancer Board, 1331 29th Street NW, Calgary, AB T2N 4N2, Canada
Breast Cancer Res 10:R98. 2008..Altered expression of decorin and lumican is associated with breast tumors. We hypothesized that genetic variation in the decorin (DCN) and lumican (LUM) genes may contribute to breast cancer... - Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriersSusan L Neuhausen
Department of Epidemiology, University of California Irvine, 224 Irvine Hall, Irvine, CA 92697, USA
Breast Cancer Res 11:R76. 2009..In this study, we investigate the association of variants in genes involved in IGF signaling and risk of breast cancer in women who carry deleterious BRCA1 and BRCA2 mutations... - Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancerJingmei Li
Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, Sweden
Breast Cancer Res 12:R19. 2010..In this study, we evaluate the association between mammographic density and genetic variants of the estrogen metabolic pathway... - Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants?Paul K Lovelock
Queensland Institute of Medical Research, PO Royal Brisbane Hospital, Herston Road, Queensland 4029, Australia
Breast Cancer Res 9:R82. 2007.... - Linkage analysis of obesity phenotypes in pre- and post-menopausal women from a United States mid-western populationLinda E Kelemen
Department of Population Health Research, Alberta Health Services Cancer Care, Calgary, AB, Canada
BMC Med Genet 11:156. 2010..Women are also more likely to distribute weight in the abdomen following menopause. We investigated whether genetic loci link with obesity-related phenotypes differently by menopausal status... - No association between a candidate TCF7L2 variant and risk of breast or ovarian cancerEllen L Goode
Health Sciences Research, Mayo Clinic College of Medicine, Rochester, USA
BMC Cancer 9:312. 2009..No studies of ovarian cancer have been reported to date... 
The prevalence of BRCA2 mutations in familial pancreatic cancerFergus J Couch
Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Cancer Epidemiol Biomarkers Prev 16:342-6. 2007..A total of 10 carriers from 180 families were identified, suggesting that BRCA2 mutations account for 6% of moderate and high-risk pancreatic cancer families...- Assessment of functional effects of unclassified genetic variantsFergus J Couch
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
Hum Mutat 29:1314-26. 2008.... - Germ line Fanconi anemia complementation group C mutations and pancreatic cancerFergus J Couch
Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Cancer Res 65:383-6. 2005..Taken together these data support the assertion that inherited mutations in FANCC can predispose to pancreatic cancer... - Association of breast cancer susceptibility variants with risk of pancreatic cancerFergus J Couch
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
Cancer Epidemiol Biomarkers Prev 18:3044-8. 2009..Recently, several breast cancer susceptibility loci have been identified through genome-wide association studies. Here we evaluated possible associations between these single nucleotide polymorphisms (SNP) and pancreatic cancer risk... - Association of mitotic regulation pathway polymorphisms with pancreatic cancer risk and outcomeFergus J Couch
Department of Laboratory Medicine and Pathology, Stabile 2 42, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA
Cancer Epidemiol Biomarkers Prev 19:251-7. 2010..Single nucleotide polymorphisms (SNP) in regulators of mitosis may promote chromosome missegregation and influence pancreatic cancer and/or survival... - Is BRCA1 associated with familial breast cancer in India?Fergus J Couch
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
Cancer Biol Ther 1:22-3. 2002 - AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 studyFergus J Couch
Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN 55905, USA
Cancer Epidemiol Biomarkers Prev 16:1416-21. 2007..In summary, the F31I polymorphism in AURKA is not associated with a modified risk of breast cancer in BRCA1 and BRCA2 carriers... - Genetic epidemiology of BRCA1Fergus J Couch
Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Cancer Biol Ther 3:509-14. 2004..In this review the current knowledge of the genetic epidemiology of BRCA1 is presented and the issues that still need to be addressed in this field are outlined... - A comprehensive examination of CYP19 variation and breast densityJanet E Olson
Division of Epidemiology, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN 55901, USA
Cancer Epidemiol Biomarkers Prev 16:623-5. 2007 - Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous studyNoralane M Lindor
The Department of Medical Genetics, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
Fam Cancer 9:495-502. 2010..7%. PENN II model for BRCA1/2 prediction performed well in this population with higher AUC compared with our experience using four other models. The ease of use of the PENNII model is compatible with busy clinical practices... - ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriersCamilo Adem
Division of Laboratory Genetics, Mayo Clinic and Foundation, Rochester, Minnesota, USA
Genes Chromosomes Cancer 41:1-11. 2004.... - Strong evidence of a genetic determinant for mammographic density, a major risk factor for breast cancerCeline M Vachon
Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Cancer Res 67:8412-8. 2007..4 cM). The putative locus on chromosome 5p is likely to account for up to 22% of variation in MD. Hence, 1 or more of the 45 candidate genes in this region could explain a large proportion of MD and, potentially, breast cancer... - A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genesDouglas F Easton
Genetic Epidemiology Unit, Strangeways Research Laboratories, University of Cambridge, Cambridge, UK
Am J Hum Genet 81:873-83. 2007..In addition to their utility for improved genetics counseling of patients and their families, the global assessment reported here will be invaluable for validation of functional assays, structural models, and in silico analyses... - Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancerAlison M Hosey
Centre for Cancer Research and Cell Biology, Queen s University Belfast, 97 Lisburn Rd, Belfast, Northern Ireland, BT9 7BL, UK
J Natl Cancer Inst 99:1683-94. 2007..We examined a possible mechanism for the observed ER alpha-negative phenotype of BRCA1-mutant tumors... - Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistanceMatthew P Goetz
Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Clin Cancer Res 14:5864-8. 2008..We sought to determine the combined effect of inherited (CYP2D6) and somatic (HOXB13/IL17BR) gene variation in tamoxifen-treated breast cancer... - A candidate tumor suppressor HtrA1 is downregulated in ovarian cancerJeremy Chien
Mayo Clinic Cancer Center and Department of Experimental Pathology, Mayo Clinic, Rochester, MN 55905, USA
Oncogene 23:1636-44. 2004..These observations raise the possibility of HtrA1 as a candidate tumor suppressor involved in promoting serine-protease-mediated cell death and that downregulation of HtrA1 in ovarian cancer may contribute to malignant phenotype... - Allele-specific expression in the germline of patients with familial pancreatic cancer: an unbiased approach to cancer gene discoveryAik Choon Tan
The Institute for Computational Medicine, Johns Hopkins University, Baltimore, Maryland, USA
Cancer Biol Ther 7:135-44. 2008.... - Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancersWataru Sakai
Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
Nature 451:1116-20. 2008..Our results suggest that secondary mutations that restore the wild-type BRCA2 reading frame may be a major clinical mediator of acquired resistance to platinum-based chemotherapy... - Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriersAntonis C Antoniou
Cancer Research UK, Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, UK
Am J Hum Genet 82:937-48. 2008.... - Functional assays for classification of BRCA2 variants of uncertain significanceDaniel J Farrugia
Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Cancer Res 68:3523-31. 2008.... - Spontaneous vulvar papillomas in a colony of mice used for pancreatic cancer researchNaomi M Gades
Department of Comparative Medicine, Mayo Clinic, Scottsdale, AZ, USA
Comp Med 58:271-5. 2008..Therefore, we speculate that interaction between the genetic background of the mice and the introduced Kras oncogene may be responsible for these papillomas... 
Mutational analysis of thirty-two double-strand DNA break repair genes in breast and pancreatic cancersXianshu Wang
Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Cancer Res 68:971-5. 2008....- Genome-wide association study identifies novel breast cancer susceptibility lociDouglas F Easton
CR UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK
Nature 447:1087-93. 2007..05 level compared with an estimated 1,343 that would be expected by chance, indicating that many additional common susceptibility alleles may be identifiable by this approach... - An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA)Georgia Chenevix-Trench
Queensland Institute for Medical Research, Brisbane, Australia
Breast Cancer Res 9:104. 2007.... - A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifenMatthew P Goetz
Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
Clin Cancer Res 12:2080-7. 2006..In the adjuvant treatment of estrogen receptor (ER)-positive breast cancer, additional markers are needed to identify women at high risk for recurrence... - Cancer risk assessment at the atomic levelAlvaro N A Monteiro
Risk Assessment, Detection, and Intervention Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
Cancer Res 66:1897-9. 2006.... - Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashesMatthew P Goetz
Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
J Clin Oncol 23:9312-8. 2005..Polymorphisms in tamoxifen metabolizing genes affect the plasma concentration of tamoxifen metabolites, but their effect on clinical outcome is unknown... - Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancerSean T Martin
Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD 21205 2196, USA
Oncogene 24:3652-6. 2005..37, 95% CI: 0.61-9.27). The increased prevalence of the BRCA2 K3326X polymorphism in patients with familial pancreatic cancer suggests that this polymorphism is deleterious and contributes to pancreatic cancer risk... - Fanconi anemia complementation group D2 (FANCD2) functions independently of BRCA2- and RAD51-associated homologous recombination in response to DNA damageAkihiro Ohashi
Department of Laboratory Medicine and Pathology, College of Medicine, Rochester, Minnesota 55905, USA
J Biol Chem 280:14877-83. 2005..Our results suggest that FANCD2 mediates double strand DNA break repair independently of Rad51-associated homologous recombination... - Utilizing Nottingham Prognostic Index in microarray gene expression profiling of breast carcinomasDylan V Miller
Department of Anatomic Pathology, Mayo Clinic, Rochester, MN 55906, USA
Mod Pathol 17:756-64. 2004..These data add support to the assertion that prognostic groups of breast carcinoma are reflected in distinguishable expression profiles of a limited set of genes... - The 17q23 amplicon and breast cancerColleen S Sinclair
Division of Experimental Pathology, Mayo Clinic, Rochester, MN, USA
Breast Cancer Res Treat 78:313-22. 2003.... - BRCA2 and pancreatic cancerAli Naderi
Department of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
Int J Gastrointest Cancer 31:99-106. 2002.... - TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumorsColleen S Sinclair
Department of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
Cancer Res 62:3587-91. 2002..TBX2 was determined to be preferentially amplified and overexpressed in BRCA1 and BRCA2 mutant tumors, whereas RPS6KB1 was not, suggesting a role for TBX2 amplification in the development of BRCA1- and BRCA2-associated breast tumors... - Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2Bing Xia
Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, Massachusetts 02115, USA
Mol Cell 22:719-29. 2006..Thus, PALB2 licenses key cellular biochemical properties of BRCA2 and ensures its tumor suppression function... - Functional assays for BRCA1 and BRCA2Marcelo A Carvalho
Department of Risk Assessment, Detection, and Intervention, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
Int J Biochem Cell Biol 39:298-310. 2007..Here we advocate the use of functional assays to complement genetic data in the analysis of unclassified missense mutations and propose a set of standards to conduct and interpret these assays... - Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancerSimon A Gayther
Translational Research Laboratories, University College London, London, United Kingdom
Cancer Res 67:3027-35. 2007..This study highlights the need for multicenter collaborations for genetic association studies... - RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studiesAntonis C Antoniou
Cancer Research UK, Genetic Epidemiology Unit, Strangeways Research Laboratory, Cambridge, CB1 8RN, UK
Am J Hum Genet 81:1186-200. 2007..Thus, 135G-->C may modify the risk of breast cancer in BRCA2 mutation carriers by altering the expression of RAD51. RAD51 is the first gene to be reliably identified as a modifier of risk among BRCA1/2 mutation carriers... - Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysisMarcelo A Carvalho
Risk Assessment, Detection, and Intervention Program, H Lee Moffitt Cancer Center, University of South Florida College of Medicine, 12902 Magnolia Drive, Tampa, FL 33612, USA
Cancer Res 67:1494-501. 2007..These results bring functional assays for BRCA1 closer to clinical applicability... - BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinicHelen A Shih
Abramson Family Cancer Research Institute and Department of Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
J Clin Oncol 20:994-9. 2002..To determine the prevalence of BRCA1 and BRCA2 mutations in families identified in a breast cancer risk evaluation clinic... - Gene-expression-based predictors for breast cancerMatthew P Goetz
N Engl J Med 356:752; author reply 752-3. 2007 - A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approachesJanet E Olson
Department of Health Sciences Research, Division of Epidemiology, Mayo Clinic College of Medicine, Rochester, MN 55901, USA
Breast Cancer Res Treat 102:237-47. 2007..We recently published resequencing data on 88 polymorphisms identified in that gene. The hypothesis tested in this study was that polymorphisms, or haplotypes, in CYP19 are related to risk of breast cancer... - A common coding variant in CASP8 is associated with breast cancer riskAngela Cox
Sheffield University Medical School, Sheffield S10 2RX, UK
Nat Genet 39:352-8. 2007..02-1.13) and 1.16 (95% c.i.: 1.08-1.25), respectively; P(trend) = 2.8 x 10(-5)). These results demonstrate that common breast cancer susceptibility alleles with small effects on risk can be identified, given sufficiently powerful studies... - The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifenMatthew P Goetz
Department of Oncology, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN, 55905, USA
Breast Cancer Res Treat 101:113-21. 2007.... - Altered expression of FANCL confers mitomycin C sensitivity in Calu-6 lung cancer cellsJun Zhang
Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Cancer Biol Ther 5:1632-6. 2006..This suggests that the correlation of an intact FA-BRCA pathway with MMC resistance may emerge as a common mechanism underlying resistance to DNA crosslinking agents in cancer patients... - Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage ConsortiumDeborah Thompson
CRC Genetic Epidemiology Unit, Strangeways Research Laboratories, University of Cambridge, Cambridge CB1 4RN, United Kingdom
Proc Natl Acad Sci U S A 99:827-31. 2002..65 was -11.0]. We conclude that, if a susceptibility gene does exist at this locus, it can only account for a small proportion of non-BRCA1/2 families with multiple cases of early-onset breast cancer... - p53 mediates repression of the BRCA2 promoter and down-regulation of BRCA2 mRNA and protein levels in response to DNA damageKangjian Wu
Department of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, 1001 Guggenheim Building, 200 First Street SW, Rochester, MN 55905, USA
J Biol Chem 278:15652-60. 2003..Thus, BRCA2 levels in the cell are regulated by three independent mechanisms in a p53-dependent manner... - Truncating variants in p53AIP1 disrupting DNA damage-induced apoptosis are associated with prostate cancer riskXianshu Wang
Department of Laboratory Medicine, Mayo Clinic/Mayo Clinical Medical College, Rochester, Minnesota 55905, USA
Cancer Res 66:10302-7. 2006.... - Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2David E Goldgar
International Agency for Research on Cancer, Lyon, France
Am J Hum Genet 75:535-44. 2004..These results provide a demonstration of the utility of the model... - Functional evaluation and cancer risk assessment of BRCA2 unclassified variantsKangjian Wu
Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Cancer Res 65:417-26. 2005..This combined approach represents a useful means of addressing the functional significance and cancer relevance of UCVs in BRCA2... - The role of Tbx2 and Tbx3 in mammary development and tumorigenesisMatthew Rowley
Department of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
J Mammary Gland Biol Neoplasia 9:109-18. 2004..Here we review the current information on the roles of Tbx2 and Tbx3 in mammary gland development and tumorigenesis...
Research Grants
- BRCA2 missense mutations and breast cancerFergus Couch; Fiscal Year: 2009..study the cancer relevance of many missense mutations will have been determined and provided to the carriers who will then be able to benefit from improved cancer risk assessment, cancer prevention and perhaps even therapeutic strategies ..
- A genome-wide association study for breast cancer in BRCA1 mutation carriersFERGUS JOSEPH COUCH; Fiscal Year: 2010..The modifiers may also lead to development of improved risk assessment models that better discriminate between high and lower risk BRCA1 mutation carriers. ..
- Genetic epidemiology of cell division regulation in breast cancerFERGUS JOSEPH COUCH; Fiscal Year: 2010..The results will provide information for improved risk assessment and could provide targets for breast cancer prevention and therapeutic agents. ..
- BRCA2 missense mutations and breast cancerFERGUS JOSEPH COUCH; Fiscal Year: 2010..relevance of many missense mutations will have been determined and provided to the carriers who will then be able to benefit from improved cancer risk assessment, cancer prevention and perhaps even therapeutic strategies ..
- BRCA2 missense mutations and breast cancerFergus Couch; Fiscal Year: 2009..relevance of many missense mutations will have been determined and provided to the carriers who will then be able to benefit from improved cancer risk assessment, cancer prevention and perhaps even therapeutic strategies ..
- BRCA2 missense mutations and breast cancerFergus Couch; Fiscal Year: 2007..study the cancer relevance of many missense mutations will have been determined and provided to the carriers who will then be able to benefit from improved cancer risk assessment, cancer prevention and perhaps even therapeutic strategies ..
- Characterization of the Chromosome 17q23 AmpliconFergus Couch; Fiscal Year: 2006..Thus, the project may involve a complete transition from benchtop to bedside. Finally, the amplified and overexpressed genes may prove useful as important targets of gene, pharmacological, and immunological therapy in the future. ..
- P21 INDUCTION BY BRCA2Fergus Couch; Fiscal Year: 2002....
- Genetic epidemiology of cell division regulation in breast cancerFergus Couch; Fiscal Year: 2009..The results will provide information for improved risk assessment and could provide targets for breast cancer prevention and therapeutic agents. ..